Trial Profile
Multicenter, Randomized and OpenⅡb Clinical Trials to Evaluate the Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients Harbouring T790M Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Furmonertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Allist Pharmaceuticals
- 08 Jun 2021 Results of post-hoc analysis assessing progression pattern and post-progression treatment presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results assessing efficacy and safety of Alflutinib in patients with EGFR T790M mutated non-small cell lung cancer (NSCLC) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 02 Jan 2020 Planned End Date changed from 1 Nov 2019 to 1 Dec 2020.